Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: Clin Cancer Res. 2009 Feb 1;15(3):960–970. doi: 10.1158/1078-0432.CCR-08-1611

Fig. 1. Anti B7−1/B7−2 antibody treatment reduced Treg both in the thymus and periphery of normal mice and delayed the development of palpable tumors.

Fig. 1

C57BL/6 mice were injected i.p. with either anti B7−1/B7−2 mAbs (1:1 mixture of 100μg 3A12 and 100μg GL-1), or control IgG (1:1 mixture of 100μg hamster and 100μg rat IgG) at 6 weeks old, 5 times every other day. The mice were sacrificed 8 days after the last injection. Thymocytes and splenocytes were harvested and analyzed by flow cytometry. Plots shown are from CD4+ cells among the lymphocyte gates. a. Anti B7−1/B7−2 antibody treatment did not alter the number of thymocytes, spleen cells and CD4 and CD8 subsets. b. Anti B7−1/B7−2 antibody treatment reduced CD25+Foxp3+ cells both in thymus and spleen. Statistical analysis was done using the Student T test. *, P<0.05; **, P<0.01. c. Kaplan Meier analysis of tumor incidence. The experimental endpoint is 2 cm in tumor diameter as determined by palpation. Data shown have been repeated 3 times.